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fever virus pathogenesis
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Crimean‑Congo hemorrhagic fever virus (CCHFV) is a tick‑borne pathogen causing a febrile illness in 
humans, which can progress to hemorrhagic manifestations, multi‑organ failure, and death. Current 
mouse models of CCHFV infection reliably succumb to virus challenge but vary in their ability to reflect 
signs of disease similar to humans. In this study, we established a signal transducer and activator 
of transcription 2 (STAT 2) knockout hamster model to expand the repertoire of animal models of 
CCHFV pathogenesis that can be used for therapeutic development. These hamsters demonstrated 
a systemic and lethal disease in response to infection. Hallmarks of human disease were observed 
including petechial rash, blood coagulation dysfunction, and various biochemistry and blood cell 
count abnormalities. Furthermore, we also demonstrated the utility of this model for anti‑CCHFV 
therapeutic evaluation. The STAT2 knock‑out hamster model of CCHFV infection may provide some 
further insights into clinical disease, viral pathogenesis, and pave the way for testing of potential drug 
and vaccine candidates.
Crimean-Congo hemorrhagic fever virus (CCHFV) is a segmented, negative-sense RNA virus belonging to the 
Orthonairovirus genus within the Nairoviridae family. Endemic in Africa, Southeast Europe, the Middle East 
and Asia, CCHFV causes a severe and sometimes fatal disease in humans with a case fatality rate ranging from 
3–80%1–8. CCHFV is transmitted from Hyalomma ticks to humans, wildlife, and  livestock9. Transmission can also 
occur through direct contact with fluids or tissues of infected livestock or patients and can lead to nosocomial 
outbreaks of CCHFV in the hospital setting. Disease in humans begins as a febrile illness including fever, chills, 
headache, and muscle soreness, which can either resolve or progress to a hemorrhagic state. The hemorrhagic 
state includes petechiae, liver necrosis, hemorrhaging of internal organs, shock, and death can occur from 
multi-organ  failure10–15. Neurological illness associated with CCHFV infection has also been  documented14–18. 
Laboratory findings associated with mortality in humans include elevated liver enzymes, thrombocytopenia, 
intravascular coagulopathy, and cytokine  responses5,16,19–29. Though there are no licensed therapeutics to treat 
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CCHFV infection, ribavirin, a nucleoside analog, has demonstrated efficacy against several viruses and has been 
proposed as a possible treatment. However, its efficacy against CCHFV in humans continues to be the subject 
of much  debate11–13.
To improve therapeutic development for CCHFV, animal models of CCHFV pathogenesis used for pre-clinical 
testing should ideally exhibit both similar clinical signs of human disease and similar laboratory findings associ-
ated with mortality in humans. Cynomolgus macaques are the only immunocompetent animal model demon-
strating both of these  characteristics30. However, the non-human primate model for CCHFV faces limitations 
for evaluation of medical countermeasures because it is not consistently lethal and is associated with increased 
cost and limited availability. Adult immunocompromised mice have been established as a cost-effective and 
practical model for the study of CCHFV pathogenesis and drug evaluation. Signal transducer and activator of 
transcription (STAT ) 1 gene knockout (STAT1−/−) mice 31, IFN α/β receptor gene knockout (IFNAR−/−)  mice31–34, 
adult wild-type mice subject to antibody-mediated disruption of type I IFN  signalling35, and humanized mice 
expressing human immune cells (Hu-NSG-SGM3)36 have been established as lethal mouse models of CCHFV 
infection. While these small animal models have been useful for further understanding CCHFV pathogenesis, 
they vary in their ability to exhibit similar clinical signs of human disease and similar laboratory findings associ-
ated with mortality in humans.
Recently, golden Syrian hamsters (Mesocricetus auratus) devoid of functional STAT2 (STAT2−/−) have dem-
onstrated success in modeling viral infection and have been used to highlight the importance of the type I IFN 
response in viral control of human adenovirus 37–40. The STAT 2 gene deletion in this model was shown to impair 
type I interferon signalling, impairing gene transcription induced by IFN-α and IFN-β, delaying production of 
IFNα transcripts, and decreasing the production of MHC-1 transcripts. However, the generation of an antibody 
and T-cell response were seemingly  unchanged38. Furthermore, there were no observed deficiencies in IFN-γ and 
IL-4  transcripts38. We aimed to expand the repertoire of small animal models available for the study of CCHFV 
pathogenesis and pre-clinical testing of therapeutics by characterizing the progression of CCHFV-associated 
disease in a lethal  STAT2−/− hamster model.
Methods
Ethics and biosafety. All animal work was approved by the Animal Care Committee of the Canadian Sci-
ence Centre for Human and Animal Health following the guidelines of the Canadian Council for Animal Care. 
All work with infectious material was conducted in the Biocontainment Level 4 (BSL-4) suite at the National 
Microbiology Laboratory (Winnipeg, Canada) following approved standard operating procedures.
Cells, virus, antivirals, and animals. Human adrenal gland/cortex SW13 cells (ATCC, VA, USA) were 
cultured in L15 media (Leibovitz’s L15 media, ThermoFisher Scientific, ON, Canada) with 10% fetal bovine 
serum (FBS). Cells were incubated in  H2O-saturated atmosphere conditions at 37 °C with no  CO2. The strain 
IbAr10200 of CCHFV (Accession No: NC_005300.2, NC_005300.1, NC_005302.3) was a kind gift from the 
University of Texas Medical Branch (Galveston, Texas). IbAr10200 was cultured in SW13 cells using L15 media 
supplemented with 1% FBS. Commercial ribavirin (R&D Systems, Minneapolis, MN) was dissolved in PBS for 
treatment of hamsters.  STAT2−/− hamsters were developed and bred at the Department of Animal, Dairy, and 
Veterinary Sciences at Utah State  University41.
Hamster infections and treatment. Groups of both male and female STAT2−/− hamsters aged 6–8 weeks 
were provided by Dr. Zhongde Wang from the Department of Animal, Dairy, and Veterinary Sciences at Utah 
State University. The STAT2−/− hamster strain comprises F2 homozygotes derived from an LVG golden Syrian 
hamster female genetically modified by CRISPR/Cas9-mediated mutation of the STAT2 N-terminal  domain41. 
On 0 days post-infection (dpi), hamsters were anesthetized by inhalation of isoflurane and virus was delivered by 
intraperitoneal, intramuscular, or subcutaneous routes of inoculation in 100 µl, 2 × 50 µl, or 200 μl of L15 media, 
respectively. Clinical signs and weights were recorded daily. On sacrifice days, hamsters were anesthetized by 
inhalation of isoflurane, bled by cardiac puncture and euthanized by anesthetic overdose with isoflurane. Blood 
was divided for blood chemistries, total cell blood counts, coagulation assays, cytokine profiling, and antibody 
detection. Tissues were harvested and fixed in 10% neutral buffered formalin for pathology or homogenized in 
L15 media and clarified by centrifugation for viral titration on SW13 cells. A set of animals (n = 9) were treated 
with 100 mg/kg/day of Ribavirin (100 μl) beginning on 1 dpi or 2 dpi. Hamsters were treated with 100 mg/kg/
day of Ribavirin for two days and then the dose of Ribavirin was dropped to 75 mg/kg/day for a further 12 days. 
Trial bleeds were conducted on treated hamsters on 3 dpi and 6 dpi to test for the presence of virus. A set of 
three animals were humanely euthanized at 8 dpi and serum was collected. Animals were euthanized when they 
reached humane endpoints, defined as exhibiting multiple of the following signs: Abnormal swelling, protrusion 
(hernia, rupture), abnormal discharge, severe dehydration, twitching, tremors, convulsions, paralysis, unsteady 
gait, lameness, muscle flaccidity, rigidity or weakness. Immediate euthanasia was conducted for animals that 
demonstrated either > 20% weight loss or unresponsiveness. The remaining survivors at the termination of the 
study (26 dpi) were humanely euthanized and terminally bled for serum collection.
Viral titrations. SW13 cells were seeded onto 96-well dishes one day prior to infection. Blood, heart, lung, 
liver, spleen, and kidney tissues were homogenized in 500 μl of L15/1% FBS using a TissueLyserII at a frequency 
of 30 for 6 min (QIAGEN, Limburg, Netherlands). The homogenates were clarified by centrifugation at 10,000 g 
for 10 min and supernatants were serially diluted in L15/1% FBS. 100 μl of each virus dilution was added to the 
cells in each well. The presence of viral-induced cytopathic effect (CPE) was read at 7 dpi by the appearance of 
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rounded cells and/or destruction of the monolayer and  TCID50 values were calculated according to Spearman-
Karber  method42. Each biological sample was tested in triplicate.
Histopathologic and immunohistochemistry analysis. For histopathological studies, lung, kidney, 
and heart samples were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 5 µm and 
stained with hematoxylin and eosin for examination on the Mirax Midi imaging system. For immunohisto-
chemistry, paraffin tissue sections were rehydrated through a series of xylene and decreasing ethanol concentra-
tions. Antigen retrieval was then performed in Biocare’s Decloaking Chamber using 10 mM Na Citrate 6.0 pH 
for 15 min at 110 °C. After cooling, protocol was followed according to the manufactures instructions for the 
Anti-Mouse HRP Cell and Tissue IHC Staining Kit (R&D Systems, CTS002). Slides were blocked both with the 
peroxidase blocking reagent and serum blocking reagent followed by an avidin block. All rinses were performed 
with 1X TBS-Tween. The slides were then incubated overnight in a 1:200 dilution of a mouse monoclonal anti-
body specific for CCHFV nucleoprotein (N) (NR-40257, a gift from BEI resources). Slides were then rinsed 
again with 1X TBS-Tween and then incubated with the biotinylated secondary antibody supplied by the kit for 
30 min, followed by incubation of HSS-HRP for 30 min. DAB was then applied for two minutes and then rinsed 
with distilled water. Slides were then counterstained with hematoxylin 7,211 (Richard Allen Scientific), dehy-
drated through a series of increasing ethanol concentrations to xylene and then cover-slipped with Permount 
mounting medium.
Hematologic, coagulation, and blood chemistry. Complete blood counts were obtained using a 
VetScan HM5 (Abaxis Veterinary Diagnostics) as per manufacturer’s instructions and serum biochemistry was 
analyzed using a VetScan VS2 (Abaxis Veterinary Diagnostics) using comprehensive profile discs in accordance 
with manufacturer’s instructions. To measure coagulation parameters a Start4 instrument (Diagnostica Stago) 
was used according to manufacturer’s instructions.
Immunoassays. To quantify serum IgG raised in  STAT2−/− hamsters infected with CCHFV, anti-CCHFV 
nucleoprotein IgG ELISAs were conducted. Briefly, 96-well half area flat-bottom high-binding microplates 
(Corning, New York, USA) were coated with recombinant CCHFV nucleoprotein diluted in sodium bicarbo-
nate (50  mM) at a concentration of 1.25  µg/mL and incubated at 4  °C overnight. Wells were washed using 
PBS-T (PBS, 0.05% Tween-20) and blocked in diluent (PBS, 5% milk, 0.5% Tween-20) at room temperature 
for 1 h. Serum from  STAT2−/− hamsters was two-fold serially diluted in diluent. Diluted samples were added 
to corresponding wells of the coated ELISA plates and incubated at 37 °C for 1 h. Plates were washed six times 
with PBS-T. Goat anti-hamster IgG horse radish peroxidase-conjugated antibody (KPL Inc., Gaithersburg, USA) 
diluted 1 in 10,000 was added to each well of the microplate. The plates were allowed to incubate at 37 °C for 1 h. 
Plates were washed six times with PBS-T. ABTS peroxidase substrate (KPL Inc., Gaithersburg, USA) was added 
to each of the wells of the microplate. Plates were allowed to incubate at room temperature for 30 min. Plates 
were read at 405 nm using a plate reader. The mean optical densities (ODs) of uninfected hamster serum at each 
dilution and standard deviations were calculated. Positive binding results for infected hamsters were character-
ized ODs by being three standard deviations greater than the mean ODs of the uninfected hamster serum at 
the corresponding dilution. The endpoint titer of a given sample was calculated as the highest dilution giving a 
positive binding result.
Quantitative real‑time PCR assay and cytokine analysis. RNA was extracted from whole blood 
following the protocol for Viral RNA Mini kit (QIAGEN, Limburg, Netherlands). cDNA was synthesized using 
0.5 µg total RNA following the protocol for RT2 First Strand Kit (QIAGEN, Limburg, Netherlands). Quantita-
tive real-time PCR for cytokine expression was conducted following the protocol for TaqMan Gene Expression 
Master Mix (Applied Biosystems, California, USA). Primers and probes targeting hamster-specific cytokine 
genes (IL-2, IL-4, IL-6, IL-10, IP-10, iNOS, β2M, TGF-β, p27, VEGF, TNF-α and IFN-γ), as well as the RPL-18 
internal reference gene, were developed  previously43 and used at final concentrations of 900-nM and 250-nM, 
respectively. The final reaction volume was 20 µL and the thermal cycling conditions for the qRT-PCR assay 
were as follows: initial denaturation at 95 °C for 3 min followed by 40 cycles of denaturation at 95 °C for 20 s and 
annealing/extension at 60 °C for 35 s. The Comparative CT method described  previously44 was used to quantify 
relative cytokine expression.
Statistical analysis. One-way ANOVA followed by Dunnett’s multiple comparisons tests was performed 
using GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego California USA, www.graph 
pad.com). Means and standard errors are reported.
Results
Susceptibility of  STAT2−/− hamsters to lethal disease via multiple routes of CCHFV infection. It 
has been well established that adult, immunocompetent animals including Syrian hamsters are refractory or not 
susceptible to clinical disease manifestations following inoculation with  CCHFV45,46 (Rosenke, Safronetz, Feld-
mann unpublished data). To establish an alternative small animal model of CCHFV infection, we assessed the 
susceptibility of STAT2−/− hamsters to 10,000  TCID50 CCHFV inoculation via intraperitoneal, intramuscular, 
and subcutaneous route. STAT2−/− hamsters demonstrated disease and mortality by all routes of infection tested. 
Animals infected by the subcutaneous or intraperitoneal routes had a mean time to death of 8.3 dpi and animals 
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infected intramuscularly had a mean time to death of 9.6 dpi (Fig. 1). All animals were euthanized by 12 dpi 
upon observing the predetermined humane endpoints.
Disease course and systemic distribution of CCHFV in  STAT2−/− hamsters. Since subcutaneous 
inoculation resulted in lethal infection and more closely mimics the natural route of infection by intradermal 
tick bite, this route was used for all subsequent experiments. We inoculated STAT2−/− hamsters with ten-fold 
serial dilutions of virus and monitored for weight loss and clinical signs of disease to establish the median 
(50%) lethal dose  (LD50) of CCHFV administered subcutaneously and characterize the time course and signs 
of disease progression. The CCHFV strain IbAr10200 had an  LD50 of 1  TCID50 IFU, with 50% of animals suc-
cumbing to infection between 10 and 22 dpi (Fig. 2a). This is similar to those described or inferred from previ-
ous reports using immunodeficient murine models, often with different viral titration methods and inoculation 
routes 31–34 though hamsters demonstrated a prolonged disease course. Hamsters typically died between 9 and 
13 dpi when inoculated with 10 and 100  TCID50 IFU, doses which consistently killed 100% of animals (Fig. 2a). 
Animals with fatal disease typically showed significant weight loss (> 20%) (Fig. 2b). Additionally euthanasia 
decisions were based on a combination of other clinical manifestations, some or all of which were present days 
prior to euthanasia (hunched posture, ruffled and dull coat condition, aggressive behaviour, severe dehydration, 
lethargy, laboured breathing, disorientation and jerky movements) or immediately perimortem (righting reflex 
issues and/or hind limb paralysis, approximately 70% of animals; visible ocular, anal, or petechial hemorrhaging, 
approximately 40%).
To characterize viral replication and tropism in the STAT2−/− hamster model of CCHFV infection, hamsters 
were infected subcutaneously with 100  LD50 (100  TCID50) of CCHFV and serially sampled on 2, 4, 6, 8 and 10 
dpi for temporal analysis of viral kinetics. Blood and organs were harvested and analyzed for the presence of 
virus (Fig. 2c). Virus was detected in all samples tested but was found at the highest levels in the lung, liver and 
spleen. Virus replication peaked in the blood at 8 dpi and then declined on 10 dpi, the termination point of the 
study (Fig. 2c). The levels of virus found in the heart and kidney appeared to follow a similar trend as with the 
blood, where a decline at later time points was observed (Fig. 2c). However, viral replication continued to increase 
in the spleen, lungs, and to a lesser degree in the liver (Fig. 2c), despite the decreasing replication elsewhere.
Figure 1.  Assessment of multiple routes of infection of CCHFV in STAT2−/− hamsters. Hamsters were infected 
with 10,000  TCID50 IbAr10200 CCHFV by either the intraperitoneal, intramuscular or subcutaneous route of 
infection (n = 3). Percent survival (a) and percent body weight (b) was determined throughout infection was 
calculated. One-way ANOVA followed by Dunnett’s multiple comparisons tests was performed using GraphPad 
Prism version 8.0.0 for Windows (GraphPad Software, San Diego California USA, www.graph pad.com). Means 
and standard errors are reported.
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Pathological findings in  STAT2−/− hamsters infected with CCHFV. Gross pathological changes were 
observed in organs of  STAT2−/− hamsters infected with 100  LD50 (100  TCID50) of CCHFV during disease pro-
gression. Compared to control animals, enlarged spleens were first observed at 4 dpi, the appearance of pale 
livers and kidneys started at 6 dpi, and the development of hemorrhages on the skin and surface of the liver 
were noticed between 8 and 10 dpi. Histopathology and IHC analysis were performed on the liver, spleen, lungs, 
kidney and heart tissues of infected and mock-infected animals collected at each time-point. Tissues from all 
mock-infected animals exhibited normal pathology and no viral antigen was detected at any time-point (Figs. 3, 
4, 5). Histologic examination showed the liver and spleen to be the primary organs of infection with pathologic 
changes apparent beginning on 4 dpi and increasing over the course of the disease (Figs. 3, 4). Liver contained 
multiple foci of hepatocellular necrosis and inflammation throughout the tissue by 6 dpi (Fig. 3). By 8 dpi loss 
of hepatic architecture, necrosis and areas of intense inflammatory infiltration were extensive (Fig. 3). Stain-
ing for CCHFV antigen was not detected at 2 dpi but by 4 dpi small numbers of hepatocytes, either alone or in 
small groups, had cytoplasmic immunoreactivity in at least 50% of hamsters (Fig. 3). At least 40% of hepatocytes 
stained positive for CCHFV antigen by 8 dpi. Loss of lymphocytes was observed in splenic white pulp in addi-
tion to some infiltration of neutrophils starting at 4 dpi when staining of viral antigen was apparent within foci 
of cells (Fig. 4). By 6 dpi virus immunoreactivity was prominent throughout the tissue. No discernable virus 
induced pathology was noted in the kidney, heart and lungs of either mock- or infected hamsters (Fig. 5). How-
ever, immunoreactive cells were widespread in lung tissues, particularly the epithelial and endothelial cells and 
alveolar septal cells, from 6 dpi onwards (Fig. 5). Individual or small foci of cells stained positive for CCHFV 
antigen in kidney and heart tissues (Fig. 5).
Serological findings in  STAT2−/− hamsters infected with CCHFV. During disease progression, sig-
nificant increases in circulating white blood cells were observed in CCHFV-infected animals compared to con-
Figure 2.  LD50 determination and virus distribution of CCHFV in STAT2−/− hamsters. Hamsters were 
subcutaneously infected with various doses of IbAr10200 CCHFV (n = 6). Percent survival (a) and percent body 
weight (b) was determined. In a follow-up study, hamsters were subcutaneously infected with 100  LD50 (100 
 TCID50) of CCHFV, humanely euthanized at 2, 4, 6, 8 and 10 dpi (n = 5/time point) and cardiac blood, heart, 
lungs, liver, spleen and kidneys were harvested and tittered for the presence of CCHFV on SW13 cells (c). One-
way ANOVA followed by Dunnett’s multiple comparisons tests was performed using GraphPad Prism version 
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trol animals at 6, 8 and 10 dpi, with a spike in lymphocytes observed at the termination time point, 10 dpi 
(Fig. 6). Monocytes demonstrated an upward trend over time but the only statistically significant increase com-
pared to control animals occurred at 8 dpi (Fig. 6). The presence of circulating neutrophils in the blood spiked 
at 6 and 8 dpi and then returned to baseline at 10 dpi when the experiment was terminated, suggesting possible 
early release of neutrophils from the bone marrow, exhaustion of neutrophil production, or stress-related demar-
gination causing the rapid influx of neutrophils into the blood and then the rapid infiltration into tissues (Fig. 6). 
The latter supports our pathology data, which first detected neutrophils in the spleen at 4 dpi. Red blood cells, 
and hemoglobin levels were unaffected by infection. Platelet counts, however, were affected by infection and 
demonstrated a complex pattern, with a steadily decreasing trend between 0 and 6 dpi, followed by a significant 
elevation by 10 dpi (Fig. 6).
Figure 3.  Liver histopathology and immunohistochemistry evaluation of STAT2−/− hamsters infected with 
CCHFV. Hamsters were subcutaneously infected with 100  LD50 (100  TCID50) of IbAr10200 CCHFV. Animals 
were humanely euthanized at 2, 4, 6, 8 and 10 dpi (n = 5/time point) with liver samples harvested at each time 
point. Tissues were stained with hematoxylin and eosin or with a mouse antibody against the CCHFV NP 
antigen. Pathologic changes and viral staining were apparent by day 4 post infection and increased over time. 
The liver displayed foci of hepatocellular necrosis and inflammation by 4 dpi which was extensive throughout 
the tissue by day 6 after infection. Bar = 200 µm.
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Blood chemistries were assessed throughout CCHFV infection in  STAT2−/− hamsters. Albumin (Alb) and 
total protein (TP) decreased over the course of disease; however, globulin levels began to increase at later time 
points (Fig. 7), suggesting that protein synthesis remained functional and the decrease in Alb and TP was due to 
losses from the digestive or renal systems. While not statistically significant, ALT levels were elevated at early time 
points during infection indicative of early signs of liver damage (Fig. 7). ALP levels were significantly elevated at 
later time points, suggesting widespread tissue dysfunction given its released from multiple sources: liver, heart 
and muscle tissue (Fig. 7). This finding is supported by the pathology findings observed, describing late-stage liver 
cirrhosis due to infection with CCHFV in the STAT2−/− hamsters. BUN, creatinine and K + levels make it unclear 
whether renal function is affected, even though there was active virus replication, visual changes in kidney tissue 
colouration, and foci of CCHFV-specific immunoreactivity in the tissues of the kidneys.
Blood coagulation factors were assessed from fresh plasma at the time of sample collection. Increasing clotting 
times were observed for prothrombin and activated partial thromboplastin (Fig. 8). Thrombin times remained 
Figure 4.  Spleen histopathology and immunohistochemistry evaluation of STAT2−/− hamsters infected with 
CCHFV. Hamsters were subcutaneously infected with 100  LD50 (100  TCID50) of IbAr10200 CCHFV. Animals 
were humanely euthanized at 2, 4, 6, 8 and 10 dpi (n = 5/time point) with spleen samples harvested at each 
time point. Tissues were stained with hematoxylin and eosin or with a mouse antibody against the CCHFV NP 
antigen. Pathologic changes and viral staining were apparent by day 4 post infection and increased over time. 
Marked loss of white pulp and virus staining was evident in spleen tissue by day 4 after infection. Bar = 200 µm.
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stable except for a transient decline in clotting time at 4 dpi and then returned to baseline levels. Interestingly, 
this decline at 4 dpi correlated with a significant increase in fibrinogen concentrations while at all other time 
points, baseline levels were maintained. There were no statistically significant changes in the percentage of protein 
C, although the pattern of changes is noteworthy. Levels increased from baseline to 4 dpi, became exhausted 
at 6 dpi, and then continued to increase until the time of termination (Fig. 8). These results could be indicative 
of disseminated intravascular coagulation. The ability to replenish the protein levels also indicate that protein 
synthesis remains intact, while decreased levels are caused by protein consumption or loses.
Immunological findings in  STAT2−/− hamsters infected with CCHFV. Since immunological rea-
gents for hamsters are limited, RNA was extracted from whole blood and various cytokine/chemokine transcript 
levels were assessed by quantitative RT-PCR. We tested 14 different cytokines and chemokines and were unsuc-
cessful at detecting mRNA transcripts or were unable to calculate a fold change due to undetectable baseline 
levels in the mock-infected animals for six of the cytokines (IL2, IL4, IL6, IL10, IP10, and iNOS). However, we 
were able to detect and calculate fold changes for 8 of the cytokines we assessed (Fig. 9a). Bcl2, Mx2 and VEGF 
did not show any significant changes in their transcript levels; however, β2M, TGFβ, p27, TNFα and IFNγ tran-
scripts were upregulated at various time points during infection (Fig. 9a). The presence of β2M, TGFβ,and TNFα 
transcripts were significantly upregulated in the blood at early time points during infection, usually between 2 
and 4 dpi; while, p27 transcripts were increased at later time points during infection at 8 dpi, and finally IFNγ 
transcripts were significantly upregulated at both 4 and 8 dpi (Fig. 9a). These results suggest that some innate 
immune responses mounted upon infection remained functional in the immunodeficient STAT2−/− hamster 
model. Since cytokine activation was limited we wanted to determine whether this model was also capable of 
producing an adaptive antibody response. Attempts at generating an ELISA to detect anti-CCHFV IgM antibod-
ies were unsuccessful. However, we were able to develop an anti-CCHFV IgG assay and serum collected from 
infected animals was assayed. Anti-CCHFV nucleoprotein-specific IgG antibodies were detected in 60% of ham-
sters at 8 dpi and 100% of hamsters had detectable levels at 10 dpi (Fig. 9b). These data demonstrate that while 
some aspects of the immune response are impaired by the knock out of the STAT2 gene, these animals were still 
capable of developing antibodies targeting CCHFV nucleoprotein in response to infection.
Figure 5.  Immunohistochemistry evaluation of STAT2−/− hamsters infected with CCHFV. Hamsters were 
subcutaneously infected with 100  LD50 (100  TCID50) of IbAr10200 CCHFV. Animals were humanely euthanized 
at 2, 4, 6, 8 and 10 dpi (n = 5/time point) and lungs, kidneys and heart were harvested. Tissues were stained with 
hematoxylin and eosin or with a mouse antibody against the CCHFV NP antigen. Shown are representative 
images from animals 8 dpi, approximately two days after initial antigen staining appeared in these tissues and 
a time corresponding to peak antigen staining. No virus-induced pathology was noted in the kidney, heart or 
lungs of either mock- or infected hamsters. Immunoreactive cells for CCHFV antigen were widespread in lung 
tissues, particularly the epithelial and endothelial cells and alveolar septal cells, from day 6 onwards. Small foci 
or individual cells stained in kidney and heart tissues. Bar = 50 µm.
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Application in antiviral evaluation. The efficacy of ribavirin for the treatment of CCHFV infection 
remains the subject of much debate in both human cases and existing small animal models. To evaluate the util-
ity of the  STAT2−/− hamster model to test therapeutics against CCHFV, hamsters were infected with 100  LD50 of 
CCHFV (100  TCID50) and treated with ribavirin beginning on either 1 or 2 dpi. Hamsters were treated with a 
loading dose of 100 mg/kg/day of ribavirin for two days and then the dose of ribavirin was dropped to 75 mg/
kg/day for 12 additional days. All ribavirin-treated animals survived infection, showed no signs of weight loss, 
and were terminated on 26 dpi at the completion of the study, while all PBS treated animals demonstrated rapid 
weight loss and were humanely euthanized by 10 dpi (Fig. 10a,b). Viremia was detected in treated animals at 3 
and/or 6 dpi but not at 26 dpi (Fig. 10c). When the presence of anti-CCHFV IgG antibodies were assessed, 2 of 
the 6 ribavirin-treated animals had detectable levels at 8 dpi and 100% of animals that began treatment at 2 dpi 
still had detectable levels at 26 dpi, while animals that began treatment 1 dpi had no detectable antibody levels 
(Fig. 10d).
Figure 6.  Hematology assessment in CCHFV-infected STAT2−/− hamsters. Hamsters were subcutaneously 
infected with 100  LD50 (100  TCID50) of IbAr10200 CCHFV. Animals were humanely euthanized at 2, 4, 6, 8 
and 10 dpi (n = 5/time point) and whole blood was collected and total cell counts were determined. One-way 
ANOVA followed by Dunnett’s multiple comparisons tests was performed using GraphPad Prism version 8.0.0 
for Windows (GraphPad Software, San Diego California USA, www.graph pad.com). Means and standard errors 
are reported. *P < 0.05, **P < 0.01, ***P < 0.001, compared to mock-infected animals.
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Discussion
CCHFV is a zoonotic virus that causes disease in humans and in severe cases leads to death. With the growing 
understanding of prognostic factors that predict mortality in human CCHFV cases, the ideal animal model for 
the evaluation of therapeutic agents should exhibit similar signs and laboratory findings in order to better predict 
drug efficacy in humans. In this study, we established the first lethal hamster model for the study of CCHFV dis-
ease and pathogenesis. Lethally infected STAT2−/− hamsters exhibit extended time to death (9–13 dpi) compared 
with the STAT1−/−31 and IFNAR−/−32–34 mouse models of CCHFV which succumb to illness at 2–5 dpi, but shorter 
than the Hu-NSG-SGM3 humanized mouse model (13–23 dpi)36. CCHFV infection in the STAT2−/− hamsters 
consists of an incubation period between 1 and 5 dpi where there are no clinical signs of infection, followed by 
the manifestation of disease on day 6 post-infection which continues until the animals reach their euthanasia 
endpoints. This finding aligns well with the time course of human fatalities, which includes an incubation time 
of 1–13 days, followed by a disease state for 5–14 days prior to  death47.
Figure 7.  Evaluation of clinical blood chemistries of STAT2−/− hamsters infected with CCHFV. Hamsters were 
subcutaneously infected with 100  LD50 (100  TCID50) of IbAr10200 CCHFV. Animals were humanely euthanized 
at 2, 4, 6, 8 and 10 dpi (n = 5/time point) and serum was collected and various biochemical markers were 
assessed. One-way ANOVA followed by Dunnett’s multiple comparisons tests was performed using GraphPad 
Prism version 8.0.0 for Windows (GraphPad Software, San Diego California USA, www.graph pad.com). Means 
and standard errors are reported. *P < 0.05, **P < 0.01, ***P < 0.001, compared to mock-infected animals.
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The STAT2−/− hamster model for CCHFV infection demonstrated signs of human infection not yet character-
ized in previous small animal models. To our knowledge, this is the first small animal model for CCHFV in which 
splenomegaly, petechial rash and orbital bleeding were observed. These findings align with studies identifying 
petechiae as a prognostic factor in human CCHFV  infections15,18, as well as a recent study characterizing CCHFV 
infection in non-human  primates30. Furthermore, this model also captures clinical signs that are associated with 
neurologic illness observed in some human  cases48–53 and characterized in the Hu-NSG-SGM3 humanized mouse 
 model36. Future CCHFV studies using the STAT2−/− hamster model may investigate whether these observations 
are significant between infected and non-infected animals, as well as surviving and non-surviving animals.
Decreased fibrinogen, prothrombin elongation, and activated partial thromboplastin time are coagulation 
findings associated with mortality in human cases of  CCHFV14,15,18. Similarly, the STAT2−/− hamster model estab-
lished in this study exhibits a similar dysregulation of both the extrinsic (prothrombin elongation) and intrinsic 
(activated partial thromboplastin elongation) coagulation pathways upon infection, whereas IFNAR−/− mice 
only demonstrate increased clotting times for activated partial thromboplastin and no change in prothrombin 
clotting  times34. In contrast, fibrinogen is increased upon infection in this model, similar to findings observed in 
the  IFNAR−/− mouse  model34, but not observed in human cases. This finding also correlated with a decrease in 
Figure 8.  Observing of coagulation parameters following CCHFV infection in STAT2−/− hamsters. 
Hamsters were subcutaneously infected with 100  LD50 (100  TCID50) of IbAr10200 CCHFV. Animals were 
humanely euthanized at 2, 4, 6, 8 and 10 dpi (n = 5/time point). Fibrinogen, thrombin time, activated partial 
thromboplastin time, prothrombin time and protein C percentages were measured. One-way ANOVA followed 
by Dunnett’s multiple comparisons tests was performed using GraphPad Prism version 8.0.0 for Windows 
(GraphPad Software, San Diego California USA, www.graph pad.com). Means and standard errors are reported. 
*P < 0.05, **P < 0.01, ***P < 0.001, compared to mock-infected animals.
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thrombin clotting time, suggesting an abundance of fibrinogen substrate for the production of fibrin by throm-
bin. Both fibrinogen and thrombin levels returned to baseline levels at 6 dpi and for the duration of infection. 
This increase in fibrinogen for both the IFNAR−/− and STAT2−/− models may be a rodent-specific observation. 
Alternatively, fibrinogen is a marker of early inflammation; therefore, it is possible we are observing a spurious 
increase rather than a true rise in coagulopathy. Thrombocytopenia is a significant prognostic factor in human 
CCHF cases which has also been demonstrated in the STAT1−/−, IFNAR−/− and humanized mouse models for 
CCHFV infection. As expected, there was an observed trend of platelet decline in the STAT2−/− hamsters by 6 
dpi, but interestingly peaked again by 10 dpi. To date, it remains controversial whether an increase or decrease 
in white blood cells (leukocytosis and leukopenia, respectively) is associated with mortality in human CCHF 
cases. In contrast to the STAT1−/− mouse model which displays leukopenia, the STAT2−/− hamster exhibits an 
increase in white blood cells similar to the Hu-NSG-SGM3 humanized mouse model upon infection. A decline 
in liver function is a hallmark of hemorrhagic fever  viruses54–59. The pattern of liver disease was notable in the 
STAT2−/− hamsters. We observed a significant amount of viral replication and pathology in the liver in infected 
hamsters. ALT levels demonstrated relatively little increase compared to the extent of damage seen by pathology. 
This could be due to an insensitive ALT assay or very rapid progression to liver damage, making the brief ALT 
rise difficult to observe. Together, this demonstrates the onset of liver failure due to infection with CCHFV and 
mimics the findings observed in humans and in the IFNAR−/− and STAT1−/− mouse  models14–16,18,31,34.
As expected, the STAT2−/− hamsters exhibited impairment in the Type 1 IFN response, shown by a lack of 
change in the expression of bcl-2 and absence of iNOS and IP-10 induction upon infection. However, similar to 
the STAT1−/− and IFNAR−/− mice, the STAT2−/− hamsters developed an increase in TNF-α, a prognostic factor 
in human CCHF  cases17. Unfortunately, we were unable to observe any changes in IL-6 and IL-8, which are also 
predictive indicators of mortality in humans. At 2 dpi, we observed a significant increase in expression of β2M, 
a plasma protein subunit of MHC class I and other class I-like molecules (CD1, Qa) in humans. β2M is upregu-
lated and shed by lymphocytes upon stimulation with IFN-γ, which occurred in the STAT2−/− hamsters upon 
Figure 9.  Immune responses following CCHFV infection in STAT2−/− hamsters. Hamsters were subcutaneously 
infected with 100  LD50 (100  TCID50) of IbAr10200 CCHFV. Animals were humanely euthanized at 2, 4, 6, 8 
and 10 dpi (n = 5/time point). Fold changes of β2M, Mx2, TGF-β, VEGF, p27, TNF-α, Bcl-2, and IFN-γ were 
calculated (a). One-way ANOVA followed by Dunnett’s multiple comparisons tests was performed using 
GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego California USA, www.graph pad.
com). Means and standard errors are reported. *P < 0.05, **P < 0.01, ***P < 0.001, compared to mock-infected 
animals. Reciprocal endpoint dilutions (b) were expressed as the reciprocal of the lowest serum dilution giving a 
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Figure 10.  Efficacy determination of Ribavirin treatment on STAT2−/− hamsters infected with CCHFV. Hamsters were 
subcutaneously infected with 100  LD50 (100  TCID50) of IbAr10200 CCHFV. Animals received two daily 100 mg/kg doses of 
Ribavirin beginning on 1 (n = 9)or 2 dpi (n-9), the daily dose was then reduced to 75 mg/kg and administered for a further 
12 days. Percent survival (a) and weight loss (b) was monitored daily (n = 6). Trial bleeds were collected from hamsters on 
day 3 and 6 (n = 3) and terminal bleeds were conducted at the termination of the experiment (n = 6). Viremia was determined 
by  TCID50 (c). One-way ANOVA followed by Dunnett’s multiple comparisons tests was performed using GraphPad Prism 
version 8.0.0 for Windows (GraphPad Software, San Diego California USA, www.graph pad.com). Means and standard errors 
are reported. (d) Three animals were euthanized on 8 dpi and the remaining six animals were euthanized at the termination of 
the study on 26 dpi. The presence of CCHFV-specific IgG antibodies were detected from serum. Reciprocal endpoint dilutions 
were expressed as the reciprocal of the lowest serum dilution giving a positive binding result compared with the negative 
control. The mean and standard error is shown for each time point.
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 infection60. The increase in β2M could suggest T-cell activation, which is elicited by a variety of viral  infections61 
and remains functional in this immunodeficient model of infection. We also assessed the ability of this model 
to generate CCHFV-specific antibodies. Presence of anti-CCHFV IgG antibodies was first detected at 8 dpi, a 
late stage of infection. After treatment with ribavirin we were able to detect the presence of CCHFV-specific 
antibodies at 8 dpi in 33% of animals and then 100% of animals that began treatment 2 dpi had detectable levels 
of CCHFV-specific antibodies at 26 dpi. The presences of antibodies in the other models were neither assessed 
nor  detected31,32,34,36. The ability of the STAT2−/− hamster model to generate antibodies in response to infection is 
encouraging and would suggest that this platform could be used to not only test for potential therapeutic agents 
but also vaccine candidates.
Finally, we showed that ribavirin could prevent mortality of STAT2−/− hamsters infected with CCHFV, dem-
onstrating the model’s ability to be used for the evaluation of promising CCHFV therapeutic candidates. The 
efficacy of ribavirin against CCHFV mortality demonstrated in this study aligns with the results of a similar 
evaluation in which 100% of STAT1−/− mice were protected from CCHFV challenge when ribavirin treatment 
was initiated at 1  dpi31. In contrast, ribavirin was ineffective in  IFNAR−/− mice, demonstrating only 14% survival 
when administered on 0  dpi33. The latter study implemented a different CCHFV isolate and may explain the 
change in outcome. However, a recent study using the same IFNAR−/− mouse platform demonstrated similar 
results, a 0% and a 33% survival rate when IbAr10200 and Hoti strains were employed, respectively, suggesting 
that ribavirin may not be a suitable candidate for the treatment of CCHFV infection or that its success may be 
model  dependent62. The ambiguous efficacy of ribavirin in preventing fatality in animal models mirrors that in 
humans, which shows benefit in some studies but ineffectiveness in  others5,11,63–68. However, these findings may 
provide insights into host factors that work synergistically or antagonistically with ribavirin treatment. Further-
more, the heterogeneity in ribavirin efficacy in humans may be in part due to relatively late administration of 
the treatment. This animal model could be used to define a window of efficacy for ribavirin, which could better 
inform clinical practice.
The STAT2−/− hamster model of CCHFV infection builds upon findings from previous rodent models and 
demonstrates a comprehensive disease profile mimicking many aspects of human infection. The model was able 
to recapitulate a variety of clinical signs observed in humans, with the visualization of petechial rash and orbital 
hemorrhaging being unique characteristics that makes it distinctive from other animal models. Additionally, 
the presence of altered liver enzymes, coagulation markers and changes in cell blood counts are also representa-
tive of the disease profile in humans. This lethal model demonstrates viremia and widespread virus replication 
throughout a variety of organ systems. Furthermore, the ability of this model to generate an antibody response 
and the ability to respond to antiviral treatment suggest that the STAT2−/− hamster would be a suitable model 
for the evaluation of promising antiviral drug and vaccine candidates.
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